Willkie represents Warburg Pincus, which owns approximately 55 percent of Eurand, in the transaction.
On December 1, it was announced that Axcan Holdings, Inc., a leading pharmaceutical company focused on the treatment of gastrointestinal disorders, has agreed to acquire global specialty pharmaceutical company Eurand N.V. for approximately $583 million in cash. Willkie represented Warburg Pincus, which owns approximately 55 percent of Eurand, in the transaction. Eurand, with facilities in the United States and Europe, develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Axcan is a privately held, leading global specialty pharmaceutical company with operations in the United States, the European Union and Canada. The deal was handled by partners Gregory Astrachan and Steven Gartner, and associate Christian Ercole.